The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats

Tohoku Journal of Experimental Medicine

Volumn 207, Issue 4, 2005, Pages 249-253

  Bolaman, Zahit ^a   Cicek, Ceyhan ^a   Kadikoylu, Gurhan ^a   Barutca, Sabri ^a   Serter, Mukadder ^a   Yenisey, Cigdem ^a   Alper, Gulinaz ^b  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b Department of Biochemistry   (Turkey)

Author keywords

Acute cardiotoxicity; Adriamycin; Amifostine; Catalase; Malondialdehyde

Indexed keywords

AMIFOSTINE; CATALASE; DOXORUBICIN; GLUTATHIONE; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; NONHUMAN; RAT; SPECTROPHOTOMETRY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ACUTE TOXICITY TESTS; AMIFOSTINE; ANIMALS; CATALASE; DOXORUBICIN; GLUTATHIONE; HEART DISEASES; MALE; MALONDIALDEHYDE; ORGAN SIZE; PROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 29144449476     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.207.249     Document Type: Article

References (39)

1. Aebi, H. (1984) Catalase invitro. Methods Enzymol., 105, 121-126.
2. Barutca, S., Meydan, N., Akar, H., Yavasoglu, I., Kadikoylu, G. & Bolaman, Z. (2004) Efficacy and tolerability of amifostine in elderly cancer patients. Curr. Ther. Res. Clin. Exp., 65, 113-124.
3. Bhanumathi, P., Saleesh, E.D. & Vasudevan, D.M. (1994) WR-1065 chemoprotector in adriamycin chemotherapy. Cancer Lett., 81, 171-175.
4. Bolaman, Z., Koseoglu, M.H., Demir, S., Atalay, H., Akalin, N., Hatip, I. & Aslan, D. (2001) Effect of amifostine on lipid peroxidation caused by cisplatin in rat kidney. J. Chemother., 3, 337-339.
5. Budd, G.T., Ganapathi, R., Adelstein, D.J., Pelley, R., Olencki, T., Petrus, J., McLain, D., Capizzi, R. & Bukowski, R.M. (1997) Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer, 80, 1134-1140.
6. Dobric, S., Dragojevic-Simic, V., Bokonjic, D., Milovanovic, S., Marincic, D. & Jovic, P. (1998) The efficiency of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats. J. Environ. Pathol. Toxicol. Oncol., 17, 291-299.
7. Doroshow, J.H. & Davies, K.J. (1986) Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem., 261, 3068-3074.
8. Dorr, R.T. Lagel, K. & McLean, S. (1996) Cardioprotection of rat heart myocytes with amifostine (ethyol) and its free thiol, WR-1065, in vitro. Eur. J. Cancer., 32, Suppl. 4, S21-S25.
9. Dorr, R.T. (1996) Cytoprotective agents for anthracyclines. Semin. Oncol., 23, Suppl. 18, 23-34.
10. Dragojevic-Simic, V.M., Dobric, S.L.J., Bokonjic, D.R., Vucinic, Z.M., Sinovec, S.M., Jacevic, V.M. & Dogovic N.P. (2004) Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs, 15, 169-178.
11. Herman, E.H., Zhang, J., Chadwick, D.P. & Ferrans, V.J. (2000) Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol., 45, 329-334.
12. Holford, N.H. (1996) A size standard for pharmacokinetics. Clin. Pharmacokinet., 30, 329-332.
13. Hortobagyl, G.N. (1997) Anthracyclines in the treatment of cancer. An overview. Drugs, 54, Suppl. 4, 1-7.
14. Issels, R.D. & Nagele, A. (1989) Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res., 49, 2082-2086.
15. Itoh, M., Iwai, K., Katone-Miyahara, Y., Yamada, H., Ohno, H., Yamamoto, K., Tashima, M., Inoko, M., Nohara, R. & Uchiyama, T. (2004) Successful allogeneic bone marrow transplantation for acute myelogenous leukemia after drug-induced cardiomyopathy. Tohoku J. Exp. Med., 204, 85-91.
16. Jahnukainen, K., Jahnukainen, T., Salmi, T.T., Svechnikov, K., Eksborg, S. & Soder, O. (2001) Amifostine protects against early but not late toxic effect of doxorubicin in infant rats. Cancer Res., 61, 6423-6427.
17. Kadikoylu, G., Bolaman, Z., Demir, S., Balkaya, M., Akalin, N. & Enli, Y. (2004) The effect of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum. Exp. Toxicol., 23, 29-34.
18. Kang, Y.J., Chen, Y. & Epstein, P.N. (1996) Supression of doxorubicin cardiotoxicity by overexpression of catalase in heart of transgenic mice. J. Biol. Chem., 21, 12610-12616.
19. Keizer, H.G., Pinedo, H.M., Schuurhuis, G.J. & Joenje, H. (1990) Doxorubicin (Adriamycin): a critical review of the radical-dependent mechanisms of cytotoxicity. Pharmacol. Ther., 47, 219-231.
20. Kocak, G., Erbil, K.M., Ozdemir, I., Aydemir, S., Sunar, B., Tuncel, M. & Atalay, S. (2003) The protective effect of melatonin on adriamycin induced acute cardiac injury. Can. J. Cardiol., 19, 535-541.
21. Lown, J.W., Chen, H.H., Plambeck, J.A. & Acton, E.M. (1982) Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effect. Bioch. Pharmacol., 31, 575-581.
22. Lowry, K.R., Mahan, D.C. & Corley, J.R. (1985) Effect of dietary phosphorus on selenium retention in postweaning swine. J. Anim. Sci., 60, 1438-1446.
23. Minotti, G., Cairo, G. & Monti, E. (1999) Role of iron in anthracyline cardiotoxicity: new tunes for an old song. FASEB J., 13, 199-212.
24. Nazeyrollas, P., Prevost, A., Baccard, N., Manot, L., Devillier, P. & Millart, H. (1999) Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother. Pharmacol., 43, 227-232.
25. Ohkawa, H., Ohishi, N. & Yagi, K. (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95, 351-358.
26. Pitts, M. (2002) A guide to the new ARENA/OLAW IACUC guidebook. Lab. Anim., 31, 40-42.
27. Samelis, G.F., Stathopoulos, G.P., Kotsarelis, D., Frangia, C., Dontas, I. & Karayannacos, P.E. (1998) Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187). Anticancer Res., 18, 3305-3309.
28. Santini, V. & Giles, F.J. (1999) The potential of amifostine from cytoprotectant to therapeutic agent. Haematologica, 84, 1035-1042.
29. Seymour, L., Bramwell, V. & Moran, L.A. (1998) Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev. Control, 3, 145-159.
30. Shan, K., Lincoff, A.M. & Young, J.B. (1996) Anthracyline-induced cardiotoxicity. Ann. Intern. Med., 125, 47-58.
31. Singal, P.K. & Tong, J.G. (1988) Vitamin E deficiency accentuates adriamycin-induced cardiomyopathy and cell surface changes. Mol. Cell. Biochem., 84, 163-171.
32. Spencer, C.M. & Goa, K.L. (1995) Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic protector. Drug, 50, 1001-1031.
33. Stankiewicz, A., Skrzydlewska, E. & Makiela, M. (2002) Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats. Drug Metabol. Drug Interact., 19, 67-82.
34. Steinherz, L.J., Steinherz, P.G., Tan, C.T., Heller, G. & Murphy, M.L. (1991) Cardiac toxicity 4 to 26 years after completing anthracycline therapy. JAMA, 266, 1672-1677.
35. Swain, S.M., Whaley, F.S., Gerber, M.C., Ewer, M.S., Bianchine, J.R. & Gams, R.A. (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol., 15, 1333-1340.
36. Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D. & Liu, L.F. (1984) Adriamycine induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 22, 466-468.
37. Tietze, T. (1969) Enzymic method for quantative determination of nanogram amounts of total and oxidized glutathione: application to mammalian blood and other tissues. Anal. Biochem., 27, 502-522.
38. Vermeulen, N.P. & Baldew, G.S. (1992) The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem. Pharmacol., 44, 1193-1199.
39. Zhou, S., Palmeria, C.M. & Wallace, K.B. (2001) Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol. Lett., 121, 151-157.